首页> 美国卫生研究院文献>Journal of Virology >Nonrandom Transduction of Recombinant Adeno-Associated Virus Vectors in Mouse Hepatocytes In Vivo: Cell Cycling Does Not Influence Hepatocyte Transduction
【2h】

Nonrandom Transduction of Recombinant Adeno-Associated Virus Vectors in Mouse Hepatocytes In Vivo: Cell Cycling Does Not Influence Hepatocyte Transduction

机译:小鼠肝细胞体内重组腺相关病毒载体的非随机转导:细胞周期不影响肝细胞转导

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recombinant adeno-associated virus vectors (rAAV) show promise in preclinical trials for the treatment of genetic diseases including hemophilia. Liver-directed gene transfer results in a slow rise in transgene expression, reaching steady-state levels over a period of 5 weeks concomitant with the conversion of the single-stranded rAAV molecules into high-molecular-weight concatemers in about 5% of hepatocytes. Immunohistochemistry and RNA in situ hybridization show that the transgene product is made in about ∼5% of hepatocytes, suggesting that most rAAV-mediated gene expression occurs in hepatocytes containing the double-stranded concatemers. In this study, the mechanism(s) involved in stable transduction in vivo was evaluated. While only ∼5% of hepatocytes are stably transduced, in situ hybridization experiments demonstrated that the vast majority of the hepatocytes take up AAV-DNA genomes after portal vein infusion of the vector. Two different vectors were infused together or staggered by 1, 3, or 5 weeks, and two-color fluorescent in situ hybridization and molecular analyses were performed 5 weeks after the infusion of the second vector. These experiments revealed that a small but changing subpopulation of hepatocytes were permissive to stable transduction. Furthermore, in animals that received a single infusion of two vectors, about one-third of the transduced cells contained heteroconcatemers, suggesting that dimer formation was a critical event in the process of concatemer formation. To determine if the progression through the cell cycle was important for rAAV transduction, animals were continuously infused with 5′-bromo-2′-deoxyuridine (BrdU), starting at the time of administration of a rAAV vector that expressed cytoplasmic β-galactosidase. Colabeling for β-galactosidase and BrdU revealed that there was no preference for transduction of cycling cells. This was further confirmed by demonstrating no increase in rAAV transduction efficiencies in animals whose livers were induced to cycle at the time of or after vector administration. Taken together, our studies suggest that while virtually all hepatocytes take up vector, unknown cellular factors are required for stable transduction, and that dimer formation is a critical event in the transduction pathway. These studies have important implications for understanding the mechanism of integration and may be useful for improving liver gene transfer in vivo.
机译:重组腺相关病毒载体(rAAV)在临床前试验中有望用于治疗包括血友病在内的遗传疾病。肝定向基因转移导致转基因表达缓慢上升,并在5周内达到稳态水平,同时单链rAAV分子在约5%的肝细胞中转化为高分子量的串联体。免疫组织化学和RNA原位杂交表明,转基因产物是在约5%的肝细胞中产生的,这表明大多数rAAV介导的基因表达发生在含有双链串联体的肝细胞中。在这项研究中,评估了体内稳定转导的机制。虽然只有约5%的肝细胞被稳定转导,但原位杂交实验表明,门静脉输注载体后,绝大多数肝细胞吸收了AAV-DNA基因组。将两种不同的载体一起输注或交错放置1、3或5周,在第二种载体输注5周后进行双色荧光原位杂交和分子分析。这些实验表明,少量但不断变化的肝细胞亚群允许稳定的转导。此外,在接受两种载体单次输注的动物中,约有三分之一的转导细胞含有异质串联体,这表明二聚体形成是串联体形成过程中的关键事件。为了确定整个细胞周期的进展对于rAAV的转导是否重要,从给予表达细胞质β-半乳糖苷酶的rAAV载体开始,就连续向动物灌输5'-bromo-2'-脱氧尿苷(BrdU)。 β-半乳糖苷酶和BrdU的共标记显示,对循环细胞的转导没有偏爱。通过证实在施用载体时或施用后肝脏被诱导循环的动物中rAAV转导效率没有增加,这进一步得到证实。综上所述,我们的研究表明,尽管几乎所有肝细胞都吸收了载体,但稳定的转导需要未知的细胞因子,并且二聚体形成是转导途径中的关键事件。这些研究对于理解整合机制具有重要意义,并且可能对改善体内肝脏基因转移有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号